Stryker Corporation (SYK)

Check out top investors' recommendation for SYK
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Its Reconstructive segment offers orthopaedic reconstructive implants used in hip and knee joint replacements; and trauma implant systems, as well as other related products. The company’s MedSurg segment provides surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, and reprocessed and remanufactured medical devices, as well as other medical device products for use in various medical specialties. Stryker Corporation’s Neurotechnology and Spine segment offers neurosurgical and neurovascular devices, which include products for use in endovascular techniques, products for use in traditional brain and open skull base surgical procedures, and orthobiologic and biosurgery products, as well as products for the treatment of acute ischemic and hemorrhagic stroke. This segment also develops, manufactures, and markets spinal implant products, such as cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products through direct sales, and third-party dealers and distributors in the United States and approximately 100 countries worldwide. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Josh Jennings Cowen And Company Buy   Jul 28, '17     160.00  Jul 28, '18  N/A 
Michael Matson Mizuho Securities USA Sell   Jul 28, '17       Jul 28, '18  N/A 
Rick Wise Stifel Nicolaus & Company, Inc. Buy   Jul 27, '17     158.00  Jul 27, '18  N/A 
Glenn Novarro RBC Capital Markets Buy   Jul 10, '17       Jul 10, '18  N/A 
Michael Matson Mizuho Securities USA Sell   Jun 19, '17       Jun 19, '18  N/A 
Josh Jennings Cowen And Company Buy   Apr 26, '17     150.00  Apr 26, '18  N/A 
William Plovanic Canaccord Genuity Buy   Feb 27, '17     137.00  Feb 27, '18  N/A 
Jason Mills Canaccord Genuity Buy   Feb 21, '17     137.00  Feb 21, '18  N/A 
Matthew Taylor National Bank Financial Sell   Jan 25, '17     122.00  Jan 25, '18  N/A 
Larry Biegelsen Wells Fargo Securities, Llc Buy   Jan 25, '17     134.50  Jan 25, '18  N/A 
William Plovanic Canaccord Genuity Buy   Jan 23, '17     127.00  Jan 23, '18  N/A 
Michael Matson Mizuho Securities USA Sell   Jan 18, '17       Jan 18, '18  N/A 
David Toung Argus Research Company Buy   Apr 27, '16     130.00  Apr 27, '17  N/A 
Kristen Stewart Deutsche Bank Securities Buy   Feb 01, '16   97.82  113.00  Feb 01, '17  26.28% 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Feb 01, '16   97.82  110.00  Feb 01, '17  26.28% 
Jason Wittes Brean Murray, Carret & Co. Buy   Jan 27, '16   97.26  115.00  Jan 27, '17  24.23% 
William Plovanic Canaccord Genuity Buy   Jan 27, '16   97.26  112.00  Jan 27, '17  24.23% 
William Plovanic Canaccord Genuity Buy   Oct 22, '15   97.14  112.00  Oct 22, '16  17.06% 
David Toung Argus Research Company Buy   Aug 05, '15   101.63  120.00  Aug 05, '16  16.37% 
William Plovanic Canaccord Genuity Buy   Jul 24, '15   99.51  110.00  Jul 24, '16  17.61% 
< previous123